|
|
|
Insider
Information: |
Thorp Clay |
Relationship: |
Director |
City: |
Durham |
State: |
NC |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
80,215 |
|
Indirect Shares
|
8,859,224 |
|
|
Direct
Value |
$56,731 |
|
|
Indirect Value
|
$5,666,332 |
|
|
Total
Shares |
8,939,439 |
|
|
Total
Value |
$5,723,063 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
24.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Clearside Biomedical, Inc. |
CLSD |
Director |
2023-09-25 |
40,522 |
2023-09-25 |
3,545,040 |
Premium* |
|
G1 Therapeutics Inc |
GTHX |
10% Owner |
|
0 |
2017-05-16 |
213,114 |
Premium* |
|
Phasebio Pharmaceuticals Inc |
PHAS |
Director |
2023-05-19 |
36,693 |
2023-05-19 |
3,545,040 |
Premium* |
|
Vigil Neuroscience, Inc. |
VIGL |
Director |
2022-05-17 |
3,000 |
2022-05-17 |
1,556,030 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
56,025 |
|
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
56,023 |
|
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
112,048 |
|
- |
|
GTHX |
G1 Therapeutics Inc |
10% Owner |
|
2017-05-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
213,114 |
|
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
1,598,219 |
1,654,242 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
3,321,785 |
3,433,833 |
0 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2018-10-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,158,049 |
266,481 |
0 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
10,586 |
15,432 |
0 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,144 |
17,943 |
0 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(52,397) |
0 |
0 |
- |
|
VIGL |
Vigil Neuroscience, Inc. |
Director |
|
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
1,254,335 |
1,254,335 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2022-12-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,406,507) |
3,545,040 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2022-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,522 |
16,522 |
0 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
36,693 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-07 |
4 |
OE |
$0.02 |
$478 |
I/I |
21,705 |
1,675,947 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2016-06-07 |
4 |
OE |
$0.02 |
$955 |
I/I |
43,410 |
3,477,243 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2023-09-25 |
4 |
B |
$0.86 |
$8,600 |
D/D |
10,000 |
40,522 |
2.39 |
% |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2022-12-21 |
4 |
B |
$1.02 |
$14,266 |
D/D |
14,000 |
30,522 |
2.39 |
% |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2019-11-22 |
4 |
A |
$1.05 |
$1,599,999 |
I/I |
1,518,026 |
4,984,420 |
0 |
- |
|
CLSD |
Clearside Biomedical, Inc... |
Director |
|
2018-12-06 |
4 |
B |
$1.36 |
$10,880 |
D/D |
8,000 |
8,000 |
3.92 |
- |
|
VIGL |
Vigil Neuroscience, Inc. |
Director |
|
2022-05-16 |
4 |
B |
$2.76 |
$60,221 |
I/I |
21,802 |
1,541,137 |
2.1 |
- |
|
VIGL |
Vigil Neuroscience, Inc. |
Director |
|
2022-05-17 |
4 |
B |
$2.97 |
$44,189 |
I/I |
14,893 |
1,556,030 |
2.1 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2021-08-18 |
4 |
B |
$3.00 |
$30,000 |
D/D |
10,000 |
32,943 |
2.39 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2018-12-04 |
4 |
B |
$3.13 |
$12,520 |
D/D |
4,000 |
15,799 |
3.92 |
- |
|
PHAS |
Phasebio Pharmaceuticals ... |
Director |
|
2020-11-24 |
4 |
B |
$3.50 |
$7,000 |
D/D |
2,000 |
22,943 |
2.39 |
- |
|
80 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|